Novartis says Alcon glaucoma treatment approved in EU




Novartis says Alcon glaucoma treatment approved in EUZURICH – Swiss pharmaceutical group Novartis said the European Commission has approved its eyecare unit Alcon’s Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease.

Whatapp NewsTelegram News

Alcon said in a statement on Monday the Simbrinza eye drops suspension had been approved to decrease elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.[eap_ad_2]

“We are pleased to introduce the only fixed combination therapy without a beta-blocker to help more glaucoma patients manage their progressive eye condition,” Jeff George, global head of Alcon, said in the statement. (Reuters)[eap_ad_3]

Spread the love



Whatapp News

Telegram News